Are another 5 years of adjuvant aromatase inhibitor therapy needed?

Qin-Guo Mo*, De-Quan Li*, Jian-Hong Zhong, Chang-Yuan Wei Department of Breast Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People’s Republic of China *These authors contributed equally to this workIn the recent issue of Breast Cancer: Targets and The...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mo QG, Li DQ, Zhong JH, Wei CY
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	breast cancer adjuvant endocrine therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c9509be1c44c4aa980562fdec77f0543
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c9509be1c44c4aa980562fdec77f0543
record_format	dspace
spelling	oai:doaj.org-article:c9509be1c44c4aa980562fdec77f05432021-12-02T07:19:57ZAre another 5 years of adjuvant aromatase inhibitor therapy needed?1179-1314https://doaj.org/article/c9509be1c44c4aa980562fdec77f05432016-11-01T00:00:00Zhttps://www.dovepress.com/letter-adjuvant-systemic-therapy-in-older-women-with-breast-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Qin-Guo Mo, De-Quan Li, Jian-Hong Zhong, Chang-Yuan Wei Department of Breast Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People’s Republic of China *These authors contributed equally to this workIn the recent issue of Breast Cancer: Targets and Therapy, some questions about adjuvant systemic therapy1 and bone loss and skeletal-related events in postmenopausal women with hormone receptor-positive breast cancer2 were discussed by two reviews.View original paper by Leone and colleagues.Mo QGLi DQZhong JHWei CYDove Medical Pressarticlebreast canceradjuvant endocrine therapyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 8, Pp 207-209 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer adjuvant endocrine therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	breast cancer adjuvant endocrine therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Mo QG Li DQ Zhong JH Wei CY Are another 5 years of adjuvant aromatase inhibitor therapy needed?
description	Qin-Guo Mo, De-Quan Li, Jian-Hong Zhong, Chang-Yuan Wei Department of Breast Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People’s Republic of China *These authors contributed equally to this workIn the recent issue of Breast Cancer: Targets and Therapy, some questions about adjuvant systemic therapy1 and bone loss and skeletal-related events in postmenopausal women with hormone receptor-positive breast cancer2 were discussed by two reviews.View original paper by Leone and colleagues.
format	article
author	Mo QG Li DQ Zhong JH Wei CY
author_facet	Mo QG Li DQ Zhong JH Wei CY
author_sort	Mo QG
title	Are another 5 years of adjuvant aromatase inhibitor therapy needed?
title_short	Are another 5 years of adjuvant aromatase inhibitor therapy needed?
title_full	Are another 5 years of adjuvant aromatase inhibitor therapy needed?
title_fullStr	Are another 5 years of adjuvant aromatase inhibitor therapy needed?
title_full_unstemmed	Are another 5 years of adjuvant aromatase inhibitor therapy needed?
title_sort	are another 5 years of adjuvant aromatase inhibitor therapy needed?
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/c9509be1c44c4aa980562fdec77f0543
work_keys_str_mv	AT moqg areanother5yearsofadjuvantaromataseinhibitortherapyneeded AT lidq areanother5yearsofadjuvantaromataseinhibitortherapyneeded AT zhongjh areanother5yearsofadjuvantaromataseinhibitortherapyneeded AT weicy areanother5yearsofadjuvantaromataseinhibitortherapyneeded
_version_	1718399480325210112

Are another 5 years of adjuvant aromatase inhibitor therapy needed?

Ejemplares similares